LM-101, an anti-SIRPα antibody, in patients with relapsed/refractory lymphoma and advanced head and neck cancer: an open-label, multicenter, phase 1 trial
Key Points
The study aims to evaluate the safety and initial efficacy of LM-101 in treating relapsed/refractory lymphoma and advanced head and neck cancer.
Open-label, multicenter design
Administration of LM-101 antibody
Inclusion of patients with relapsed/refractory lymphoma and advanced head and neck cancer
LM-101 was well tolerated among patients
Preliminary efficacy signal indicates potential benefit of LM-101 combined with rituximab
Abstract
LM-101 was well tolerated. The preliminary efficacy signal supports further evaluation of LM-101 plus rituximab in relapsed/refractory lymphoma.
LM-101, an anti-SIRPα antibody, in patients with relapsed/refractory lymphoma and advanced head and neck cancer: an open-label, multicenter, phase 1 trial | Synapse